Drug survival measures the length of time until discontinuation of a drug. The length of time
a patient remains on a biologic drug is impacted by several factors such as tolerability, side …

Targeting pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) has been an
effective therapeutic approach in patients with a variety of autoimmune diseases, including …

Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐
severe psoriasis are lacking. Objectives To examine safety, efficacy and time to …

Background Drug survival is a marker for treatment sustainability in chronic diseases such
as psoriasis. Objective The aim of these analyses was to assess survival of biologic …

Background GBR 830 is a humanized mAb against OX40, a costimulatory receptor on
activated T cells. OX40 inhibition might have a therapeutic role in T cell–mediated diseases …

Objective Drug survival is an important proxy measure for effectiveness of treatments for
inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) …

Background Randomized controlled trials have shown the efficacy and safety of brodalumab
in patients with moderate to severe plaque psoriasis. Objective To evaluate the efficacy and …

Background Psoriasis is a chronic, inflammatory skin disease often requiring long-term
therapy. Objective To evaluate the long-term safety and efficacy of risankizumab in patients …

In pharmaceutical research and development, pursuing novel therapeutics and optimizing
existing drugs have been revolutionized by the fusion of cutting-edge technologies and …

Introduction Interleukin-17 inhibitors are the newest class of monoclonal antibodies
approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical …